Former Woodford biotech stock on the frontlines of Covid raises £84m
LF Equity Income has already ditched the unquoted company but Schroders trust set to benefit
LF Equity Income has already ditched the unquoted company but Schroders trust set to benefit
|
|
Credit data company is more expensive than US rivals with a P/E ratio of 37.52
|
|
Fears of a second lockdown and messy Brexit negotiations spook investors
|
|
‘Investors are likely to be wary of backing a launch only to find themselves with an illiquid holding’
|
|
‘The only winners are often those able to charge fees against a fund in distress’
|
|
UPDATED: The investment trust had already announced it was jacking up its target on bumper demand
|
|
FTSE 250 fund house currently has 16 sub £100m funds
|
|
Total losses of £1.4bn in the LF Equity Income fund ‘cannot be put down to a Covid effect’
|
|
Protege Giles Rothbarth will takeover £4.5bn fund along with its Sicav equivalent
|
|
Half of the total £900m being targeted is in out-of-favour UK equities
|
|
Link admits investors might not see their money back until mid to late 2021
|
|
Both strategies pro-actively engage with developing market companies to improve their ESG credentials
|
|